Evidence map›Paper›PMID 35678576›Full record

ArticleMicrobiology spectrum2022

Rifampicin Resistance Associated with

Justine Schaeffer, Kathrin Lippert, Sonja Pleininger, Anna Stöger, Petra Hasenberger, Silke Stadlbauer, Florian Heger, Angelika Eigentler, Alexandra Geusau, Alexander Indra and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Expanded Gram-Negative Activity of Marinopyrrole A.Pathogens (Basel, Switzerland) · 2025
    Article
  3. Review
  4. PotentmSphere · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Justine SchaefferInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.ORCID 0000-0003-4311-3294
Kathrin LippertInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Sonja PleiningerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Anna StögerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Petra HasenbergerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Silke StadlbauerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Florian HegerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Angelika EigentlerMB-LAB - Clinical Microbiology Laboratory, Innsbruck, Austria.
Alexandra GeusauDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Alexander IndraInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Franz AllerbergerInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.
Werner RuppitschInstitute for Medical Microbiology and Hygiene, Austrian Agency for Health and Food Safetygrid.414107.7, Vienna, Austria.ORCID 0000-0001-9940-3333
Austrian Agency for Health and Food Safety · ATMedical University of Vienna · ATUniversity of Salzburg · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to increasing rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae, alternative treatments should be considered. To assess rifampicin's potential as a gonorrhea treatment, we used

Indexed as

GonorrheaNeisseria gonorrhoeaeAnti-Bacterial AgentsAustriaBacterial ProteinsDNA-Directed RNA PolymerasesDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationRifampinAnti-Bacterial AgentsBacterial ProteinsDNA-Directed RNA PolymerasesRifampinantibiotic resistanceNeisseria gonorrhoeaerifampicinwhole-genome sequencing

Identifiers

PMID35678576
PMCPMC9241671
OpenAlexW4281654548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.